<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003846</url>
  </required_header>
  <id_info>
    <org_study_id>99702</org_study_id>
    <secondary_id>COG-99702</secondary_id>
    <secondary_id>CCG-99702</secondary_id>
    <secondary_id>CDR0000067006</secondary_id>
    <nct_id>NCT00003846</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors</brief_title>
  <official_title>Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy&#xD;
      use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral&#xD;
      stem cell transplantation may allow doctors to give higher doses of radiation therapy and&#xD;
      chemotherapy and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of radiation therapy, chemotherapy and&#xD;
      peripheral stem cell transplantation in treating patients with primitive neuroectodermal&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of postradiotherapy high-dose consolidation chemotherapy with&#xD;
           peripheral blood stem cell (PBSC) support in patients with high-risk primitive&#xD;
           neuroectodermal tumors.&#xD;
&#xD;
        -  Determine the safety of delaying radiotherapy by approximately one month in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of thiotepa in these patients.&#xD;
&#xD;
        -  Determine the toxic effects of intensive chemotherapy with PBSC support in these&#xD;
           patients.&#xD;
&#xD;
        -  Assess the time to hematopoietic recovery after PBSC infusion when intensive&#xD;
           chemotherapy is used after craniospinal radiotherapy in these patients.&#xD;
&#xD;
        -  Determine the overall and event-free survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of thiotepa during consolidation therapy.&#xD;
&#xD;
        -  Induction: Within 31 days of initial surgery, patients receive induction therapy&#xD;
           comprising vincristine IV on day 0, cyclophosphamide IV over 2 hours on days 0 and 1,&#xD;
           and filgrastim (G-CSF) subcutaneously (SC) beginning on day 2 and continuing for at&#xD;
           least 7-10 days. Peripheral blood stem cells (PBSC) are then collected.&#xD;
&#xD;
        -  Chemoradiotherapy: After blood cell counts recover, and within 28 days of starting&#xD;
           induction, patients begin chemoradiotherapy. Patients receive vincristine IV once weekly&#xD;
           for 8 doses. Radiotherapy is administered 5 days a week, for 6 weeks, beginning within&#xD;
           the same week as the start of vincristine.&#xD;
&#xD;
        -  Consolidation: Therapy begins 4-6 weeks after the last radiation treatment in the&#xD;
           absence of disease progression. The first and third course are the same and comprise&#xD;
           vincristine IV on day 0, carboplatin IV over 1 hour on days 0 and 1, thiotepa IV over 3&#xD;
           hours on days 2-4, and G-CSF SC daily beginning on day 7. PBSC are reinfused on day 7.&#xD;
           The second course comprises vincristine IV on day 0, carboplatin IV over 1 hour on days&#xD;
           0 and 1, cyclophosphamide IV over 2 hours on days 2 and 3, and G-CSF SC daily beginning&#xD;
           on day 5. PBSC are reinfused on day 5. Each course lasts 21 days.&#xD;
&#xD;
      For consolidation therapy, cohorts of 6-12 patients each receive escalating doses of thiotepa&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which&#xD;
      no more than 2 of 12 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24-56 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Neupogen®</other_name>
    <other_name>G-CSF</other_name>
    <other_name>NSC#614629</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Paraplatin®</other_name>
    <other_name>CBDCA</other_name>
    <other_name>NSC#241240</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cytoxan®</other_name>
    <other_name>Neosar®</other_name>
    <other_name>Procytox®</other_name>
    <other_name>CPM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>TRIETHYLENETHIOPHOSPHORAMIDE</other_name>
    <other_name>THIOPLEX®</other_name>
    <other_name>TEPA</other_name>
    <other_name>NSC# 6396</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Oncovin®</other_name>
    <other_name>Vincasar®</other_name>
    <other_name>leucocristine</other_name>
    <other_name>VCR</other_name>
    <other_name>NSC# 67574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven primitive neuroectodermal tumor (PNET) of one of the following&#xD;
             types:&#xD;
&#xD;
               -  Atypical teratoid/rhabdoid tumor&#xD;
&#xD;
               -  Medulloblastoma&#xD;
&#xD;
               -  Desmoplastic medulloblastoma&#xD;
&#xD;
               -  Ependymoblastoma&#xD;
&#xD;
               -  Medullomyoblastoma&#xD;
&#xD;
               -  Spongioblastoma&#xD;
&#xD;
               -  Spongioblastoma polare&#xD;
&#xD;
               -  Primitive polar spongioblastoma&#xD;
&#xD;
               -  Medulloepithelioma&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  Pineoblastoma&#xD;
&#xD;
          -  Posterior fossa PNET must be M1-3 or M0 with greater than 1.5 cm2 residual disease&#xD;
&#xD;
          -  Non posterior fossa PNET and other types must be M0-3&#xD;
&#xD;
               -  If M3, must show clear evidence of tumor on MRI&#xD;
&#xD;
          -  No marrow involvement or other extraneural metastases&#xD;
&#xD;
          -  No M4 disease&#xD;
&#xD;
          -  No cord compression requiring emergency radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  3 to 21&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 150,000/mm^3 (no platelet transfusions)&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL (red blood cell transfusions allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or ALT less than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance or glomerular filtration rate at least 70 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Shortening fraction greater than 27% by echocardiogram OR&#xD;
&#xD;
          -  Ejection fraction greater than 47% by MUGA&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV_1/FVC greater than 60% except for children who:&#xD;
&#xD;
               -  Are uncooperative&#xD;
&#xD;
               -  Have no dyspnea at rest&#xD;
&#xD;
               -  Have no exercise intolerance&#xD;
&#xD;
               -  Have pulse oximetry greater than 94% on room air&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Steroids for increased intracranial pressure allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior urgent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior therapy for tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Stacy Nicholson, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Cancer Center at Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2004</study_first_posted>
  <last_update_submitted>July 25, 2014</last_update_submitted>
  <last_update_submitted_qc>July 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

